GoKawiilOpen Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Retraction Note: NSD2 targeting reverses plasticity and drug resistance in prostate cancer
Why This Matters
This retraction highlights the importance of rigorous validation in cancer research, especially when targeting genetic factors like NSD2 that could influence treatment resistance. For the tech industry, it underscores the need for careful peer review and reproducibility in developing targeted therapies, ultimately impacting the development of more effective cancer treatments for consumers.
Key Takeaways
- Retraction emphasizes the importance of validation in cancer research
- Targeting NSD2 may influence drug resistance in prostate cancer
- Ensures reliability and accuracy in the development of targeted therapies
Get alerts for these topics